Perkins Capital Management’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Perkins Capital Management’s Portfolio NBSE Stock Details NBSE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-6,625	Closed	-$25K	–	100
2023 Q1	$25K	Buy	6,625 +1,675	+34%	+$7.73K	0.02%	93
2022 Q4	$19K	Buy	4,950 +50	+1%	+$256	0.02%	98
2022 Q3	$39K	Buy	4,900 +825	+20%	+$13.7K	0.04%	96
2022 Q2	$86K	Buy	4,075 +750	+23%	+$17.6K	0.09%	94
2022 Q1	$125K	Buy	3,325 +1,825	+122%	+$63.1K	0.1%	96
2021 Q4	$84K	Buy	1,500 +450	+43%	+$30.2K	0.06%	100
2021 Q3	$76K	Buy	1,050 +310	+42%	+$23.7K	0.05%	99
2021 Q2	$71K	Buy	+740	New	+$81.7K	0.04%	101

Other funds holding NBSE

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

DCMIC

Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return

CMU

Carnegie Mellon University Pittsburgh, Pennsylvania $64.3M AUM 35.71% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return

JAMONY

Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Perkins Capital Management's NBSE Position: Q2 2023 in Review

Perkins Capital Management sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q2 2023, closing a stake of 6,625 shares — an estimated $25K sold.

Perkins Capital Management first reported a position in NBSE in Q2 2021 and held it in 8 quarters. The position peaked at $125K in Q1 2022. 27 funds tracked by Wall St. Rank hold NBSE as of Q2 2023.

Perkins Capital Management reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Perkins Capital Management sold 6,625 NeuBase Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $25K.
Perkins Capital Management first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q2 2021 and held it in 8 quarters.
Perkins Capital Management's NeuBase Therapeutics, Inc. Common Stock position peaked at $125K in Q1 2022.
27 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Perkins Capital Management's 13F filing for Q2 2023, filed 21 Jul 2023.